AAAAAA

   
Results: 1-25 | 26-50
Results: 1-25/50
INTERACTION OF ANTI-HIV PROTEASE INHIBITORS WITH THE MULTIDRUG TRANSPORTER P-GLYCOPROTEIN (P-GP) IN HUMAN CULTURED-CELLS
Authors: WASHINGTON CB DURAN GE MAN MC SIKIC BI BLASCHKE TF
Citation: Cb. Washington et al., INTERACTION OF ANTI-HIV PROTEASE INHIBITORS WITH THE MULTIDRUG TRANSPORTER P-GLYCOPROTEIN (P-GP) IN HUMAN CULTURED-CELLS, Journal of acquired immune deficiency syndromes and human retrovirology, 19(3), 1998, pp. 203-209
ENDOTHELIAL DYSFUNCTION IN HUMAN HAND VEINS IS RAPIDLY REVERSIBLE AFTER SMOKING CESSATION
Authors: MORENO H CHALON S URAE A TANGPHAO O ABIOSE AK HOFFMAN BB BLASCHKE TF
Citation: H. Moreno et al., ENDOTHELIAL DYSFUNCTION IN HUMAN HAND VEINS IS RAPIDLY REVERSIBLE AFTER SMOKING CESSATION, American journal of physiology. Heart and circulatory physiology, 44(3), 1998, pp. 1040-1045
A MARKOV MIXED EFFECT REGRESSION-MODEL FOR DRUG COMPLIANCE
Authors: GIRARD P BLASCHKE TF KASTRISSIOS H SHEINER LB
Citation: P. Girard et al., A MARKOV MIXED EFFECT REGRESSION-MODEL FOR DRUG COMPLIANCE, Statistics in medicine, 17(20), 1998, pp. 2313-2333
CHARACTERIZING PATTERNS OF DRUG-TAKING BEHAVIOR WITH A MULTIPLE-DRUG REGIMEN IN AN AIDS CLINICAL-TRIAL
Authors: KASTRISSIOS H SUAREZ JR KATZENSTEIN D GIRARD P SHEINER LB BLASCHKE TF
Citation: H. Kastrissios et al., CHARACTERIZING PATTERNS OF DRUG-TAKING BEHAVIOR WITH A MULTIPLE-DRUG REGIMEN IN AN AIDS CLINICAL-TRIAL, AIDS, 12(17), 1998, pp. 2295-2303
THE EXTENT OF NONADHERENCE IN A LARGE AIDS CLINICAL-TRIAL USING PLASMA DIDEOXYNUCLEOSIDE CONCENTRATIONS AS A MARKER
Authors: KASTRISSIOS H SUAREZ JR HAMMER S KATZENSTEIN D BLASCHKE TF
Citation: H. Kastrissios et al., THE EXTENT OF NONADHERENCE IN A LARGE AIDS CLINICAL-TRIAL USING PLASMA DIDEOXYNUCLEOSIDE CONCENTRATIONS AS A MARKER, AIDS, 12(17), 1998, pp. 2305-2311
ACE-INHIBITION IMPROVES ENDOTHELIAL FUNCTION IN CHRONIC SMOKERS
Authors: CHALON S MORENO H BLASCHKE TF HOFFMAN BB
Citation: S. Chalon et al., ACE-INHIBITION IMPROVES ENDOTHELIAL FUNCTION IN CHRONIC SMOKERS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 2-2
DIURNAL-VARIATION OF PLASMA L-ARGININE CONCENTRATIONS AND THE EFFECT OF DIETARY L-ARGININE INTAKE
Authors: TANGPHAO O COULSTON AM MORENO H CHALON S CHAN JR COOKE JP BLASCHKE TF HOFFMAN BB
Citation: O. Tangphao et al., DIURNAL-VARIATION OF PLASMA L-ARGININE CONCENTRATIONS AND THE EFFECT OF DIETARY L-ARGININE INTAKE, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 25-25
ASYMMETRIC DIMETHYLARGININE (ADMA) - A NOVEL RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION - ITS ROLE IN HYPERCHOLESTEROLEMIA
Authors: BOGER RH BODEBOGER SM SZUBA A TSAO PS CHAN JR TANGPHAO O BLASCHKE TF COOKE JP
Citation: Rh. Boger et al., ASYMMETRIC DIMETHYLARGININE (ADMA) - A NOVEL RISK FACTOR FOR ENDOTHELIAL DYSFUNCTION - ITS ROLE IN HYPERCHOLESTEROLEMIA, Circulation, 98(18), 1998, pp. 1842-1847
MEDICATION COMPLIANCE AS A FEATURE IN DRUG DEVELOPMENT
Authors: KASTRISSIOS H BLASCHKE TF
Citation: H. Kastrissios et Tf. Blaschke, MEDICATION COMPLIANCE AS A FEATURE IN DRUG DEVELOPMENT, Annual review of pharmacology and toxicology, 37, 1997, pp. 451-475
A SEMIPARAMETRIC METHOD FOR DESCRIBING NOISY POPULATION PHARMACOKINETIC DATA
Authors: PARK K VEROTTA D BLASCHKE TF SHEINER LB
Citation: K. Park et al., A SEMIPARAMETRIC METHOD FOR DESCRIBING NOISY POPULATION PHARMACOKINETIC DATA, Journal of pharmacokinetics and biopharmaceutics, 25(5), 1997, pp. 615-642
PHARMACOKINETICS OF SAQUINAVIR, ZIDOVUDINE, AND ZALCITABINE IN COMBINATION THERAPY
Authors: VANHOVE GF KASTRISSIOS H GRIES JM VEROTTA D PARK KS COLLIER AC SQUIRES K SHEINER LB BLASCHKE TF
Citation: Gf. Vanhove et al., PHARMACOKINETICS OF SAQUINAVIR, ZIDOVUDINE, AND ZALCITABINE IN COMBINATION THERAPY, Antimicrobial agents and chemotherapy, 41(11), 1997, pp. 2428-2432
EXPOSURE-RESPONSE RELATIONSHIPS FOR SAQUINAVIR, ZIDOVUDINE, AND ZALCITABINE IN COMBINATION THERAPY
Authors: VANHOVE GF GRIES JM VEROTTA D SHEINER LB COOMBS R COLLIER AC BLASCHKE TF
Citation: Gf. Vanhove et al., EXPOSURE-RESPONSE RELATIONSHIPS FOR SAQUINAVIR, ZIDOVUDINE, AND ZALCITABINE IN COMBINATION THERAPY, Antimicrobial agents and chemotherapy, 41(11), 1997, pp. 2433-2438
CHLOROQUINE-INDUCED VENODILATION IN HUMAN HAND VEINS
Authors: ABIOSE AK GROSSMANN M TANGPHAO O HOFFMAN BB BLASCHKE TF
Citation: Ak. Abiose et al., CHLOROQUINE-INDUCED VENODILATION IN HUMAN HAND VEINS, Clinical pharmacology and therapeutics, 61(6), 1997, pp. 677-683
HEPARIN BUT NOT ENOXAPARIN DILATES HUMAN HAND VEINS
Authors: TANGPHAO O ABIOSE A MORENO H BLASCHKE TF HOFFMAN BB
Citation: O. Tangphao et al., HEPARIN BUT NOT ENOXAPARIN DILATES HUMAN HAND VEINS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 26-26
IMPAIRED RESPONSE TO BRADYKININ IN SMOKERS REVERSES SHORTLY AFTER REFRAINING FROM SMOKING
Authors: MORENO H TANGPHAO O BLASCHKE TF HOFFMAN BB
Citation: H. Moreno et al., IMPAIRED RESPONSE TO BRADYKININ IN SMOKERS REVERSES SHORTLY AFTER REFRAINING FROM SMOKING, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 28-28
L-ARGININE DISPOSITION DOES NOT CHANGE DURING CHRONIC ADMINISTRATION TO HYPERCHOLESTEROLEMIC PATIENTS
Authors: TANGPHAO O MORENO H BLASCHKE TF HOFFMAN BB
Citation: O. Tangphao et al., L-ARGININE DISPOSITION DOES NOT CHANGE DURING CHRONIC ADMINISTRATION TO HYPERCHOLESTEROLEMIC PATIENTS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 44-44
SAQUINAVIR IS A HIGH-AFFINITY SUBSTRATE FOR THE MULTIDRUG TRANSPORTER, P-GLYCOPROTEIN
Authors: WASHINGTON CB DURAN GE SIKIC BI BLASCHKE TF
Citation: Cb. Washington et al., SAQUINAVIR IS A HIGH-AFFINITY SUBSTRATE FOR THE MULTIDRUG TRANSPORTER, P-GLYCOPROTEIN, Clinical pharmacology and therapeutics, 61(2), 1997, p.
THE CLINICAL PHARMACOKINETICS OF RIFABUTIN
Authors: BLASCHKE TF SKINNER MH
Citation: Tf. Blaschke et Mh. Skinner, THE CLINICAL PHARMACOKINETICS OF RIFABUTIN, Clinical infectious diseases, 22, 1996, pp. 15-21
PHARMACOKINETICS OF HIGH-DOSE ORAL CCNU IN BONE-MARROW TRANSPLANT PATIENTS
Authors: KASTRISSIOS H CHAO NJ BLASCHKE TF
Citation: H. Kastrissios et al., PHARMACOKINETICS OF HIGH-DOSE ORAL CCNU IN BONE-MARROW TRANSPLANT PATIENTS, Cancer chemotherapy and pharmacology, 38(5), 1996, pp. 425-430
PATIENT COMPLIANCE AND DRUG FAILURE IN PROTEASE INHIBITOR MONOTHERAPY
Authors: VANHOVE GF SCHAPIRO JM WINTERS MA MERIGAN TC BLASCHKE TF
Citation: Gf. Vanhove et al., PATIENT COMPLIANCE AND DRUG FAILURE IN PROTEASE INHIBITOR MONOTHERAPY, JAMA, the journal of the American Medical Association, 276(24), 1996, pp. 1955-1956
DO WE NEED FULL COMPLIANCE DATA FOR POPULATION PHARMACOKINETIC ANALYSIS
Authors: GIRARD P SHEINER LB KASTRISSIOS H BLASCHKE TF
Citation: P. Girard et al., DO WE NEED FULL COMPLIANCE DATA FOR POPULATION PHARMACOKINETIC ANALYSIS, Journal of pharmacokinetics and biopharmaceutics, 24(3), 1996, pp. 265-282
A TRIAL COMPARING NUCLEOSIDE MONOTHERAPY WITH COMBINATION THERAPY IN HIV-INFECTED ADULTS WITH CD4 CELL COUNTS FROM 200 TO 500 PER CUBIC MILLIMETER
Authors: HAMMER SM KATZENSTEIN DA HUGHES MD GUNDACKER H SCHOOLEY RT HAUBRICH RH HENRY WK LEDERMAN MM PHAIR JP NIU M HIRSCH MS MERIGAN TC BLASCHKE TF SIMPSON D MCLAREN C ROONEY J SALGO M
Citation: Sm. Hammer et al., A TRIAL COMPARING NUCLEOSIDE MONOTHERAPY WITH COMBINATION THERAPY IN HIV-INFECTED ADULTS WITH CD4 CELL COUNTS FROM 200 TO 500 PER CUBIC MILLIMETER, The New England journal of medicine, 335(15), 1996, pp. 1081-1090
MORPHINE-INDUCED VENODILATION IN HUMANS
Authors: GROSSMAN M ABIOSE A TANGPHAO O BLASCHKE TF HOFFMAN BB
Citation: M. Grossman et al., MORPHINE-INDUCED VENODILATION IN HUMANS, Clinical pharmacology and therapeutics, 60(5), 1996, pp. 554-560
INTRODUCING MEDICAL-STUDENTS TO MEDICATION NONCOMPLIANCE
Authors: KASTRISSIOS H FLOWERS NT BLASCHKE TF
Citation: H. Kastrissios et al., INTRODUCING MEDICAL-STUDENTS TO MEDICATION NONCOMPLIANCE, Clinical pharmacology and therapeutics, 59(5), 1996, pp. 577-582
A MARKOV MODEL FOR DRUG COMPLIANCE WITH APPLICATION TO HIV+ PATIENTS
Authors: GIRARD P SHEINER LB KASTRISSIOS H BLASCHKE TF
Citation: P. Girard et al., A MARKOV MODEL FOR DRUG COMPLIANCE WITH APPLICATION TO HIV+ PATIENTS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 1-1
Risultati: 1-25 | 26-50